A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis
M. Gironi(Don Carlo Gnocchi Foundation), Gianvito Martino(Vita-Salute San Raffaele University), Marta Radaelli(Humboldt-Universität zu Berlin), Vittorio Martinelli(Vita-Salute San Raffaele University), Sebastiano Bucello, Silvia Franchi(University of Milan), Gıancarlo Comı(Casa di Cura Columbus), Vincenzo Di Pilato(University of Genoa), Paola Sacerdote(University of Milan), Rosella Cavarretta(Don Carlo Gnocchi Foundation), Marco Cursi(Vita-Salute San Raffaele University), Raffaello Nemni(University of Milan), Filippo Martinelli Boneschi(Ollscoil na Gaillimhe – University of Galway), Claudio Solaro(Rina Services (Italy)), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), ME Rodegher, Lucia Moiola(Vita-Salute San Raffaele University)
Cited by 96
Related Papers
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
|The Lancet|2001|1.1k
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706
Ofatumumab versus Teriflunomide in Multiple Sclerosis
|New England Journal of Medicine|2020|706